Default company panoramic image
Btns 20ir 20051615b page 02

BTNS

Developing the first trillion dollar family of drugs, membrane active immunomodulators (MAIMS).

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Antonio, TX, USA
  • Currency USD
  • Founded February 2008
  • Employees 2
  • Website btnsresearch.com

Company Summary

BTNS is a small, woman owned drug development company based in San Antonio, Texas. BTNS is developing a newly discovered class of therapeutic agents, MAIMS, that change the ways that biological molecules interact at cellular membranes. MAIMS thereby control inter-cellular signaling by controlling transmembrane signal transduction. Applications include cancer, autoimmune diseases, biodefense, ionizing radiation injury and infectious disease.

Team

  • Default avatar
    Elzbieta Izbicka
    CEO

    Dr. Izbicka trained in biophysics and has more than thirty years of academic and industrial experience in drug and medical device development.

  • Dr. Streeper trained in analytical pharmacology and has more than twenty five years of academic and industrial experience in drug and medical device development.

Advisors

  • Default avatar
    Steve Wurzburg, Pillsbury Winthrop and Shaw
    Corporate Counsel
    Unconfirmed

Previous Investors

  • Default avatar
    None
    Unconfirmed